Keyphrases
Confidence Interval
100%
Chemotherapy
100%
Phase II Study
100%
Progression-free Survival
100%
Previously Treated
100%
Gemcitabine
100%
Advanced Biliary Tract Cancer
100%
Biliary Tract Cancer
100%
Ramucirumab
100%
Overall Survival
50%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
50%
Disease Control Rate
50%
Chemorefractory
50%
Treatment Duration
25%
Tumor
25%
Chemotherapy Regimen
25%
Partial Response
25%
Liver
25%
Prior Chemotherapy
25%
Pulmonary Embolism
25%
Hypertension
25%
Stage IV Disease
25%
Disease Progression
25%
Stable Disease
25%
Angiogenesis
25%
Marrow
25%
Median Progression-free Survival
25%
Median Overall Survival
25%
Overall Response Rate
25%
Proteinuria
25%
Gastrointestinal Bleeding
25%
Overall Survival Rate
25%
Restaging
25%
Mutational Status
25%
Intrahepatic Cholangiocarcinoma (iCCA)
25%
Gallbladder Cancer
25%
Single-arm Trial
25%
Extrahepatic Cholangiocarcinoma
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Progression Free Survival
100%
Gemcitabine
100%
Biliary Tract Cancer
100%
Ramucirumab
100%
Disease
80%
Overall Survival
80%
Vasculotropin Receptor 2
40%
Bile Duct Carcinoma
40%
Survival Rate
20%
Neoplasm
20%
Lung Embolism
20%
Patient History of Chemotherapy
20%
Chemotherapy Regimens
20%
Disease Exacerbation
20%
Gastrointestinal Hemorrhage
20%
Proteinuria
20%
Gallbladder Cancer
20%